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Abstract
Piericidin, rotenone and pyridaben are specific inhibitors of the NADH^ubiquinone oxidoreductase (Complex I) that bind
to its ubiquinone binding site(s). Using site directed mutagenesis, we demonstrate that residues G409, D412, R413 and V407
of the C-terminus of Complex I NUOD subunit are directly involved in the binding of these inhibitors. We propose that the
corresponding inhibitor/quinone binding site would be located close to NUOD^NUOB interface. ß 2001 Elsevier Science
B.V. All rights reserved.
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The proton pumping NADH^ubiquinone oxidore-
ductase (Complex I, EC 1.6.5.3) catalyzes the ¢rst
step of oxidative phosphorylation, i.e., the transfer
of two electrons from NADH to ubiquinone. Com-
plex I couples this oxidoreduction reaction to the
active transport of four protons across the mitochon-
drial inner membrane. This enzyme is present both in
the inner membrane of eukaryotic mitochondria and
in the plasma membrane of many bacteria, such as
Rhodobacter capsulatus (for reviews see [1]). Whereas
the mitochondrial enzyme contains up to 43 di¡erent
subunits, the bacterial enzyme is made up of only
13^14 subunits and can thus be considered as the
paradigm of the minimal core Complex I. The archi-
tecture of this membranous enzyme is re£ected in the
organization of the nuo/nqo operon encoding Com-
plex I: the 5P half of the operon encodes mainly sub-
units NUO-B, -C, -D, -E, -F, -G, and -I that con-
stitute a peripheral arm perpendicular to the
membrane plane. This domain can be subdivided
into a NADH-dehydrogenase domain, composed of
subunits NUO-E, -F and -G, which catalyzes the
oxidation of NADH, and a hinge domain composed
of subunits NUO-B, -C, -D, -I. The seven remaining
genes of the bacterial nuo operon i.e., nuoA plus nuo-
H, -J, -K, -L, -M, -N encode hydrophobic proteins
which comprise the membrane domain. Among the
di¡erent cofactors of Complex I, ubiquinone plays a
signi¢cant role: (i) as a substrate, it is the ¢nal ac-
ceptor of electrons from NADH-oxidation. (ii) as a
tightly bound cofactor, quinone has been proposed
to take part in electron recycling and/or proton
transport processes carried out by Complex I [2,3].
0005-2728 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 0 0 5 - 2 7 2 8 ( 0 1 ) 0 0 1 5 8 - X
Abbreviations: HAR, hexaammineruthenium(III) chloride;
NBQ, nonylubiquinone; I50, inhibitor’s concentration yielding
half-maximal inhibition; NADH, nicotinamide adenine dinucleo-
tide
* Corresponding author. Fax: +33-4-7688-5187;
E-mail : iprieur@cea.fr
BBABIO 40390 23-2-01
Biochimica et Biophysica Acta 1504 (2001) 173^178
www.bba-direct.com
Many inhibitors targeting Complex I such as rote-
none, piericidin and pyridaben are considered to
bind at, or close to, the quinone binding site(s) (for
reviews see [4,5]). As quinones and Complex I inhib-
itors share a hydrophobic nature, the binding site for
these species has long been considered to be buried in
the membrane domain. In fact, both photoa⁄nity
labeling experiments with rotenone analogs [6] and
Fig. 1. Strategy for the mutagenesis study of NUOD C-terminus. (A) The C-termini of bacterial (R. capsulatus and Escherichia coli)
and mitochondrial (bovine and Neurospora crassa) NUOD and 49 kDa subunits of Complex I are aligned to show the high conserva-
tion of residues targeted in this study (see arrows). This conservation also extends to the related plastidial complex (cf. rice chloro-
plast). For each enzyme complex, the preferred quinone substrate is indicated in brackets. The mutations indicated by arrows in this
panel were introduced by PCR in the 3P end of nuoD gene using the following PCR reverse primers: ACtaGCGGTCAATCTCCCC-
GAACACGACcTnCATCGTGCC (possible mutations D405CK, E, Q, Stop), GCAGCACtaGCGGTCAATCTCCCCGAACAbGA-
CATCCATC (possible mutations V407CV, L, M), AGCACtaGCGGTCAATCTCcagGAACACG (G409CL), GCAGCACtaGCGcT-
nAATCTCCCCGAACACGACATCCATC (possible mutations D412CK, E, Q, Stop) and GCAGCACtactnGTCAATCTCCCCG-
AACACGACATCCATC (possible mutations R413CK, E, Q, Stop). Bases underlined in the above sequences correspond to a BfaI
restriction site introduced as a genetic marker, whereas the mutated codons are double-underlined. Among the 14 mutations poten-
tially obtainable with this strategy, only the six mutations indicated in the ¢gure were actually generated. (B) The series of pRXxK
plasmids was generated by insertion of the mutated 3PnuoD fragments together with a KIXX interposon within a unique HindIII re-
striction site present in the suicide plasmid pRX01. Double recombination between this plasmid and R. capsulatus chromosome thus
gave a genomic construct where the ribosome binding site of nuoE gene was dissociated from the altered 3P end of the reconstructed
nuoD gene (lower part of the ¢gure).
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genetic studies [7,8] have pointed to the NUOH sub-
unit (ND1 in mitochondria) as being a good candi-
date for the binding of quinone and rotenone. How-
ever, this hypothesis was called into question by our
identi¢cation of a missense mutation in the hydro-
philic NUOD subunit of R. capsulatus that conferred
resistance of Complex I activity to piericidin and
rotenone [9]. Since Complex I contains only one ro-
tenone binding site [10], the simplest way to reconcile
these data is to postulate that the inhibitor/quinone
binding site is located at the interface between the
peripheral and membranous domains of Complex I
and involves both the NUOH and NUOD subunits
(NUOD is equivalent to the 49 kDa subunit in mi-
tochondria) [9]. This hypothesis is supported by the
observation that, in the nematode Caenorhabditis el-
egans, mutation R290K, a¡ecting the NUOD sub-
unit of Complex I, induced an hypersensitivity to
volatile anesthetics, that were reported to inhibit
Complex I activity [11]. However, it has been shown
that (tri£uoromethyl)diazirinyl[3H]pyridaben, an
analog of the inhibitor pyridaben, speci¢cally labeled
the peripheral NUOB subunit (PSST in the bovine
enzyme). As other Complex I inhibitors such as ro-
tenone and piericidin prevented this labeling, the au-
thors suggested that a unique inhibitor binding site
would be located on the NUOB subunit [12]. In the
present study, we have further assessed the involve-
ment of the C-terminus of NUOD subunit in the
binding of Complex I inhibitors. Since the C-termi-
nal region of NUOD contains amino acid residues
conserved in both prokaryotes and eukaryotes (see
Fig. 1), we developed a strategy for site directed mu-
tagenesis of this region.
For genetic manipulations of the 3P end of the
nuoD gene, we cloned the RsaI^XhoI DNA fragment
encompassing the nuoD and nuoE genes into the sui-
cide vector pPHU281 [13] yielding plasmid pRX01.
The 3P end of the nuoD gene contains the ribosome-
binding site for the contiguous nuoE gene and there-
fore cannot be easily altered. To overcome this prob-
lem, we duplicated the 3P end of the nuoD gene: 0.3
kb DNA fragments corresponding to the 3P part of
nuoD were produced by the polymerase chain reac-
tion (PCR) using a common forward primer
(CCGAGATGAAGACCTCGATGGAGGC) and
modi¢ed reverse primers (see Fig. 1). The PCR prod-
ucts were cloned together with the KIXX interposon
in the unique HindIII restriction site of pRX01. Dou-
ble recombination of the resulting pRXxK plasmids
with the chromosome of the R. capsulatus parental
B10 strain [14] yielded mutants with an entire re-
combinant nuoD gene followed by the KIXX car-
tridge and an independent ribosome binding site
for the nuoE gene (Fig. 1). The genotype of these
recombinants was checked by Southern blotting or
PCR, restriction digestion and sequencing.
This strategy was ¢rst validated by the construc-
tion of strain WDK containing a wild-type nuoD
gene. Complex I of strain WDK displayed the
Fig. 2. E¡ect of the mutations of NUOD C-terminus on the
NADH oxidoreductase activity of Complex I. All NADH oxi-
doreductase activities were measured spectrophotometrically at
30‡C (dual wavelength mode, 340 nm minus 400 nm) in KPE
bu¡er (50 mM KH2PO4/K2HPO4, 1 mM EDTA, pH 7.5) in
the presence of 10 mM KCN, 5 WM kresoxymethylbrio and 0.2
mM NADH (O= 6.2 mM31 cm31). The membranes used for
these measurements were prepared from the mutant R. capsula-
tus strains as in [9], except that the disruption step was carried
out with a Polytron (Kinematica, Germany). Measurements
were carried out triplicate (variance of each measurement is in-
dicated by a vertical bar). (A) NADH^HAR oxidoreductase ac-
tivity (measured in the presence of 2 mM HAR). (B) The
NADH^NBQ oxidoreductase activity of the mutant membranes
was titrated with increasing amounts of nonylubiquinone. The
maximal velocity (Vmax) was estimated from a Michaelian ¢t-
ting using the software Kaleidagraph and was normalized to
NADH^HAR oxidoreductase activity.
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same kinetic characteristics as the enzyme of the pa-
rental B10 strain and was therefore used as a refer-
ence throughout these studies. Using the same ap-
proach, we generated six mutants altered at the
conserved residues D405 (D405E), V407 (V407M
andV407L), G409 (G409A), D412 (D412E), R413
(R413K) of the NUOD C-terminus (Fig. 1). Mem-
branes of all the mutants, as well as WDK, presented
NADH oxidase activity, NADH^HAR (hexaammi-
neruthenium(III) chloride) oxidoreductase activity
and NADH^quinone oxidoreductase activity (Fig.
2). NADH^HAR oxidoreductase speci¢c activity is
accepted as a good estimate for the amount of active
peripheral domain associated with membranes [15].
Taking this activity as a reference, membranes of all
the mutants displayed amounts of Complex I com-
parable or higher than those of the wild-type mem-
branes (Fig. 2A). Thus, the mutations introduced did
not a¡ect the overall assembly of the Complex I in
the membrane. On the other hand, the NADH^qui-
none oxidoreductase activity of all the mutants was
signi¢cantly decreased in comparison to the wild
type. After normalization to NADH^HAR oxidore-
ductase activity to correct for the observed variabil-
ity of the Complex I concentration in the di¡erent
membrane preparations, NADH^NBQ (nonylubiqui-
none) oxidoreductase activity appeared to be de-
creased by about 50% for the D405E, V407M,
V407L, D412E mutants and by up to 72% and
81% for the R413K and G409A mutants, respectively
(Fig. 2B). These data further support the hypothesis
that the C-terminus of NUOD subunit is essential for
quinone reduction in the Complex I (see below).
Apart from the D405E and V407L mutants, all
mutants presented a clear resistance to the inhibitors
tested (Fig. 3). The V407M mutant, a control recon-
struction of the previously described mutant PiC [9],
independently con¢rmed that this single point muta-
tion in NUOD induces a strong decrease in the sen-
sitivity of Complex I to rotenone and piericidin (Fig.
3A,B). With regard to pyridaben, the mutation
V407M induced a signi¢cant but limited 1.7-fold in-
crease of Complex I resistance to pyridaben (see Fig.
3C). In comparison, extension of the lateral chain of
the same V407 residue by one carbon (V407L muta-
tion) had only a very limited e¡ect on the sensitivity
to inhibitors (a 1.5-fold increase in I50 for piericidin
and rotenone and virtually no e¡ect on pyridaben
sensitivity). The Complex I of D412E mutant dis-
played a behavior similar to that of V407M with
respect to piericidin and rotenone (I50 increased by
6-fold for piericidin and 4-fold for rotenone) (Fig.
3A). Furthermore, this mutant appeared signi¢cantly
more resistant than V407M to pyridaben (I50 in-
Fig. 3. Sensitivity of the NADH oxidase activity of mutant
membranes to piericidin, rotenone and pyridaben. Prior to mea-
surement, 0.16 mg of membranes were incubated in a KPE
bu¡er as described in Fig. 2 but omitting HAR, kresoxymethyl-
brio and KCN, for 5 min at 30‡C, in the presence of variable
concentrations of piericidin, rotenone or pyridaben. NADH oxi-
dase activity, involving the entire respiratory chain activity, was
then monitored spectrophotometrically, following NADH con-
sumption (dual wavelength mode, 340 nm minus 400 nm) using
the oxygen as a ¢nal acceptor. The resulting titration curves
were ¢tted to a Michaelian model to estimate I50 (inhibitor con-
centration yielding half-maximal inhibition). (A) I50 for the ti-
tration of inhibition by piericidin. (B) I50 for the titration of in-
hibition by rotenone. (C) I50 for the titration of inhibition by
pyridaben.
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creased by 2.6-fold). Mutation G409A had an e¡ect
similar to that of mutation V407M on pyridaben
sensitivity, but induced only a marginal resistance
to piericidin and none to rotenone. Finally, the
NADH oxidase activity of mutant R413K proved
to be 1.5 times more sensitive to piericidin than the
wild-type reference activity. It is noteworthy that for
V407M, as well as for the other mutants presented
here, the maximal inhibition by piericidin was always
greater than 90%. In other words, the observed
changes in inhibitor sensitivity were not due to any
destabilization of the enzyme leading to partially in-
sensitive NADH oxidase activity. In summary, dis-
crete alterations in a narrow region of the C-termi-
nus of NUOD subunit resulted in consistent, but
distinct e¡ects on the sensitivity of Complex I to-
wards piericidin, rotenone and pyridaben. These re-
sults ¢t well with the idea that the di¡erent Complex
I inhibitors and ubiquinone bind to overlapping but
not superimposable binding sites [4,10]. They further
support our previous supposition that the quinone
polar head binds to the peripheral NUOD subunit.
Along these lines, we also observed that the com-
mon sequence motif for quinone binding sites (ali-
phatic-(X)3-H-(X)2=3-(L/T/S)) described by Fisher
and Rich [16] is actually present in a highly con-
served domain of the NUOD N-terminus. Out of
31 mitochondrial 49 kDa subunits and three
NUOD subunits of ubiquinone-containing bacteria,
all but one contained the following quinone binding
motif: (I/V)60-(X)3-H64-(X)2-(T/S)67 (the residues
are numbered as in R. capsulatus). Considering the
primary structure of the protein, this quinone bind-
ing motif is 350 amino acids apart from the C-termi-
nus NUOD region that we identi¢ed by mutagenesis.
However, these two regions may be close together in
the fully folded protein.
As mentioned above, it was recently claimed, on
the basis of photoa⁄nity labeling experiments car-
ried out with a pyridaben analog, that the binding
site for Complex I inhibitors may be located at the
level of the NUOB peripheral subunit (PSST in mi-
tochondria) [12]. At ¢rst glance, this report is consis-
tent neither with our previously proposed model, nor
with the present results. However, protein sequence
comparisons between the subunits of Complex I and
those of NiFe hydrogenases have suggested that sub-
units NUOB and NUOD may form a catalytical
dimer involved in the coupling of proton pumping
to electron transfer [17,18]. This suggests that a cor-
responding ancestral module may have evolved to
ensure the reduction of either protons (hydrogenases)
or ubiquinone (Complex I) [19]. Furthermore, the
phylogenetic relationship between the membrane
bound NiFe hydrogenase of Methanosarcina barkeri
and a putative NUOD,-B,-I,-H,-L module of Com-
plex I gives weight to our previous proposal that a
quinone binding site would consist of a ‘quinone tail’
subsite located on NUOH subunit and a ‘quinone-
polar head’ subsite located on NUOD [9].
Finally, taking into account: (i) our observation
that NUOD subunit is involved in a quinone binding
site, (ii) the presence of a common sequence motif for
quinone binding sites on the same NUOD subunit,
(iii) the steric limits compatible with photoa⁄nity
labeling of NUOB by (tri£uoromethyl)diaziri-
nyl[3H]pyridaben), (iv) the above phylogenetic con-
siderations and (v) the distance limitations imposed
by electron transfer [20], the ‘quinone head’ subsite
borne by the NUOD subunit should be located near
to the NUOB^NUOD interface.
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